middle.news
Neurizon Secures $5.88M to Propel ALS Drug Trial Forward
10:14am on Tuesday 27th of January, 2026 AEDT
•
Biotechnology
Read Story
Neurizon Secures $5.88M to Propel ALS Drug Trial Forward
10:14am on Tuesday 27th of January, 2026 AEDT
Key Points
Raised $5.88 million via entitlement offer with strong shareholder participation
Issued 73.5 million new shares at $0.08 each
Funds to support regulatory, manufacturing, and operational activities
On track to commence HEALEY ALS Platform Trial dosing in Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE